Drug Profile


Alternative Names: Astuprotimut-R; D1/3 MAGE-3 fusion protein; D1/3 MAGE-3 fusion protein SB MAGE-3; D1/3 MAGE-3 His; D1/3 MAGE-3 His fusion protein; GSK 1572932A; GSK 2132231A; GSK 249553; GSK1203486A; MAGE-A3; MAGE-A3 antigen specific cancer immunotherapeutic; MAGE-A3 ASCI; NSC 719274; SB 249553; SB MAGE-3; SID 534984

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Ludwig Institute for Cancer Research
  • Class Cancer vaccines; Immunotherapies; Peptides; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants; MAGEA-3-protein-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Malignant melanoma
  • No development reported Multiple myeloma
  • Discontinued Bladder cancer; Non-small cell lung cancer

Most Recent Events

  • 05 Jan 2017 No development reported - Phase-I for Multiple myeloma in USA (IM)
  • 15 Apr 2016 Interim adverse events and efficacy data from a phase II trial in Malignant melanoma (Inoperable/Unresectable, Combination therapy) presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR 2016)
  • 14 May 2015 GlaxoSmithKline terminates long term follow-up of phase II trial in Malignant melanoma in Belgium and France due to lack of scientific justification to continue collect information (NCT00849875) before May 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top